At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 8 enrolled
Drug / intervention
BTG-002814drug
Likely dose
BTG-002814 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
VEROnA: A Window of Opportunity Study of Vandetanib-eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies
In Brief
A Early Phase 1 clinical trial evaluating BTG-002814 for Carcinoma, Hepatocellular and Metastatic Colorectal Cancer. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
CollaboratorsBiocompatibles UK Ltd
Timeline
Early Ph 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartMay 2017
First PostedSep 2017
Primary CompletionAug 2019
TodayJul 2026
First PostedSep 25, 2017
Enrollment StartMay 17, 2017
Primary CompletionAug 3, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.8 years ago
Interventions
BTG-002814drug
BTG-002814 containing 100 mg vandetanib